°²öÎÓéÀÖ¹ÙÍø

³£¼ûÑÛ²¡ÐÂÎÅ

µÑÕ븺ѹÎüÒý¸¨ÖúÁѿױպÏÊÖÒÕÒ½ÖδóÌØ·¢ÐԻưßÁÑ¿× Ñо¿

×÷ÕߣºÎ´Öª 2019-01-31 13:07:19
×ÖÌå´óС£º

¡¡¡¡»Æ°ßÁѿ׵ľÞϸ¶ÔÁÑ¿×ÓúºÏÓнϴóÓ°Ïì¡£2013Äê¾ÙÊÀ²£Á§Ìå»Æ°ßÇ£ÒýС×齫OCT²â¶¨µÄ>400 ¦ÌmÕß³ÆΪ´óÁÑ¿× £¬²¿·ÖÑо¿ÕßʵÑé½ÓÄÉÄÚ½çĤ°ê·­×ªÊÖÒÕ¶Ô´óIMH¾ÙÐÐÒ½ÖÎÒÔ̽ÌÖÊÇ·ñ¿ÉÌá*ÊÖÊõ ÂÊ £¬³ÉΪ½üÄêÀ´»Æ°ßÁÑ¿×ÊÖÊõµÄÑо¿ÈÈÃÅ¡£

¡¡¡¡ÄÚ½çĤ°ê·­×ªÊõÊǽâ¾ö´óIMHµÄ Ñ¡Ôñô?±¾Ñо¿ÖÐͨ¹ýÄÚ½çĤ°þ³ýÍŽáµÑÕ븺ѹÎüÒý¸¨ÖúÁѿױպÏÊÖÒÕÒ½ÖÎ408 - 939 ¦ÌmµÄIMH £¬·¢Ã÷¸ÃÒªÁì¿ÉʹÁÑ¿×ÏòÐÄÐÔËõС £¬´Ó¶øÐÞ¸´Áѿס£±¾Ñо¿ÖÐËùÓл¼ÕßÊõºóÁѿ׾ù³ÊUÐͺÍVÐÍÓúºÏ £¬ÎÞ3ÐͺÍ4ÐÍÓúºÏÕß¡£Ñо¿·¢Ã÷ £¬4ÐÍÓúºÏÕß¾Ö²¿RPEϸ°ûÍâòÉñ¾­ÊÓÍøĤ²ãȱÈç £¬¹ÊÊõºóÊÓÁ¦½Ï²î¡£ÓÐÑо¿Åú×¢ £¬IMHÊõºó4ÐÍÓúºÏÕß±È Îª10% - 20%¡£±¾×黼ÑÛÊ×´ÎÊõºóÁÑ¿×δ±ÕºÏÕßÕ¼25% £¬ÓÉÓÚÏÖÔÚ³¤Ð§ÆøÌåȱ·¦ £¬¹ÊÁÑ¿×Êõºóδ±ÕÊÊʱÐèʵʱÐв£Á§ÌåÄÚÎÞ¾ú¿ÕÆø×¢Éä £¬Ò½ÖκóÁѿ׾ù±ÕºÏ¡£ËµÃ÷ËäÈ»²£Á§ÌåÇиîÍŽá¿ÕÆøÌî³ä¿Éʹ´óIMHÓúºÏ £¬µ«¿ÕÆø³äÌîµÄÒ½ÖÎ ¿ÉÄܲ»È糤ЧÆøÌå £¬Í¬Ê±Ö¤ÊµÒ½ÖδóIMH²¢²»ÐèÒª¾ÙÐкã¾Ã²£Á§ÌåÄÚ¹èÓÍÌî³ä¡£

¡¡¡¡ÖµµÃ×¢ÖصÄÊÇ £¬Áѿ׾Þϸ²¢·ÇÊÇÓ°ÏìÊ×´ÎÊÖÊõ ÂÊµÄ Ôµ¹ÊÔ­ÓÉ £¬ÄÚ½çĤ°þ³ýÊõµÄ¼¼ÇÉÒ²ÊÇÊÖÊõ³É°ÜµÄÒªº¦¡£ÓÐȤµÄÊÇ £¬PangµÈÔÚÊÓÍøĤȫ²ãÁÑ¿×Öз¢Ã÷Óлư߰å²ãÁÑ¿×Ïà¹ØµÄÊÓÍøĤǰĤÔöÉú(lamellar hole-associated epiretinal proliferation, LHEP)¡£LHEPÊÇÊÓÍøĤ°å²ãÁÑ¿×ÍâòµÄ¡¢µ«²»Ç£À­ÊÓÍøĤµÄÒ»ÖÖËðÉËÐÞ¸´×éÖ¯ £¬¿ÉÔö½ø»Æ°ßÁÑ¿×ÓúºÏ¡£LHEPÔ´×ÔÁѿ״¦ÊÓÍøĤµÄÖÐÐIJã £¬ÑØ×é֯ȱËð²¿Î»¾­ÁÑ¿×ÔµÔöÉúÖÁÊÓÍøĤÄڲ㠣¬ÊÖÊõÖÐÄÚ½çĤµÄÏòÐÄÐÔ°þ³ý¿ÉºÜºÃµØ±£»¤LHEP £¬ÓÐÖúÓÚÁѿױßÑصÄËɽâ £¬´Ó¶øʹÁѿױպÏ¡£

¡¡¡¡ÄÚ½çĤ°ê·­×ªÊõºóÊÓÍøĤÍâ²ã×éÖ¯µÄÐÞ¸´ÊÇ·ñÀûÓÚÊÓÍøĤµÄ¹¦Ð§  £¬´Ó¶ø¸üºÃµØ »Æ°ßÇøÊÓ¹¦Ð§ÏÖÔÚ±¨µÀ½ÏÉÙ £¬±ðµÄÒ²ÉÐȱ·¦¶ÔÄÚ½çĤ°ê·­×ªÊõÓëÄÚ½çĤ°þ³ýÊõÊõºóÊÓ¹¦Ð§Ð§¹û¾ÙÐнÏÁ¿µÄÎÄÏ××ÊÁÏ¡£PakµÈÑо¿·¢Ã÷ £¬ÄÚ½çĤ°ê·­×ªÊõºó²¢Î´ÊӲ쵽ÏÔ×ŵÄÊÓÍøĤELM¼°EZµÄÐÞ¸´¡£±¾Ñо¿ÖнÓÄɵÑÕ븨ÖúµÄÁѿױպÏÊÖÒÕ £¬ÊõÖпÉÊÓ²ìÁѿ׵ÄËõСºÍ±ÕºÏ £¬ÊõºóÔçÆھͿÉÒÔÊӲ쵽ELMºÍEZȱËð¹æÄ£µÄËõС £¬ÊõºóÊÓÁ¦ÏÔ×ÅÌá* £¬ÌáÐѸÃÊõʽÓÐÖúÓڻư߹¦Ð§µÄ ¡£

·µ»Ø ÔÚÏß×Éѯ
ÍøÕ¾µØͼ